X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs DIVIS LABORATORIES - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE DIVIS LABORATORIES CADILA HEALTHCARE/
DIVIS LABORATORIES
 
P/E (TTM) x 32.8 30.0 109.2% View Chart
P/BV x 6.1 5.2 117.2% View Chart
Dividend Yield % 0.8 1.0 81.0%  

Financials

 CADILA HEALTHCARE   DIVIS LABORATORIES
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
DIVIS LABORATORIES
Mar-17
CADILA HEALTHCARE/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs4601,222 37.6%   
Low Rs305784 38.9%   
Sales per share (Unadj.) Rs92.1153.1 60.2%  
Earnings per share (Unadj.) Rs14.839.9 37.1%  
Cash flow per share (Unadj.) Rs18.544.6 41.4%  
Dividends per share (Unadj.) Rs3.2010.00 32.0%  
Dividend yield (eoy) %0.81.0 83.9%  
Book value per share (Unadj.) Rs68.0201.8 33.7%  
Shares outstanding (eoy) m1,023.74265.47 385.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.26.6 63.4%   
Avg P/E ratio x25.825.1 102.8%  
P/CF ratio (eoy) x20.722.5 92.0%  
Price / Book Value ratio x5.65.0 113.2%  
Dividend payout %21.625.0 86.3%   
Avg Mkt Cap Rs m391,581266,266 147.1%   
No. of employees `00016.99.7 173.1%   
Total wages/salary Rs m15,0024,687 320.0%   
Avg. sales/employee Rs Th5,594.54,175.0 134.0%   
Avg. wages/employee Rs Th890.1481.5 184.9%   
Avg. net profit/employee Rs Th899.91,089.3 82.6%   
INCOME DATA
Net Sales Rs m94,29540,643 232.0%  
Other income Rs m1,286749 171.7%   
Total revenues Rs m95,58141,392 230.9%   
Gross profit Rs m19,03614,460 131.6%  
Depreciation Rs m3,7501,233 304.1%   
Interest Rs m45023 1,991.2%   
Profit before tax Rs m16,12213,953 115.5%   
Minority Interest Rs m3380-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-30-   
Tax Rs m1,2893,349 38.5%   
Profit after tax Rs m15,16810,604 143.0%  
Gross profit margin %20.235.6 56.7%  
Effective tax rate %8.024.0 33.3%   
Net profit margin %16.126.1 61.7%  
BALANCE SHEET DATA
Current assets Rs m60,22340,105 150.2%   
Current liabilities Rs m53,0586,595 804.6%   
Net working cap to sales %7.682.5 9.2%  
Current ratio x1.16.1 18.7%  
Inventory Days Days70119 58.9%  
Debtors Days Days8881 109.3%  
Net fixed assets Rs m72,98419,995 365.0%   
Share capital Rs m1,024531 192.9%   
"Free" reserves Rs m68,57653,043 129.3%   
Net worth Rs m69,60053,574 129.9%   
Long term debt Rs m24,6840-   
Total assets Rs m152,20761,585 247.1%  
Interest coverage x36.8618.4 6.0%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.60.7 93.9%   
Return on assets %10.317.3 59.5%  
Return on equity %21.819.8 110.1%  
Return on capital %17.926.1 68.7%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m21,28035,384 60.1%   
Fx outflow Rs m10,87410,399 104.6%   
Net fx Rs m10,40624,985 41.6%   
CASH FLOW
From Operations Rs m13,49511,493 117.4%  
From Investments Rs m-29,103-11,372 255.9%  
From Financial Activity Rs m23,158-93 -24,874.3%  
Net Cashflow Rs m7,55628 26,605.6%  

Share Holding

Indian Promoters % 74.8 52.0 143.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 11.8 70.3%  
FIIs % 5.9 19.0 31.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 17.2 64.0%  
Shareholders   44,069 31,796 138.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   SHASUN PHARMA  WYETH LTD  GSK PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 16, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS